National Institute for Health and Care Excellence7d
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284
Suggested remit: To appraise the clinical and cost effectiveness of sebetralstat within its marketing authorisation for treating acute attacks of hereditary angioedema.
National Institute for Health and Care Excellence8d
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]
Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has ...
National Institute for Health and Care Excellence12d
Guidance, NICE advice and quality standards In development
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202 Technology appraisal guidance TBC Guselkumab for previously treated moderately to ...
National Institute for Health and Care Excellence2d
Guidance and quality standards In consultation
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment Draft guidance Health technology evaluation 8 July 2024 12 SQ-HDM SLIT for ...
National Institute for Health and Care Excellence12d
Guidance, NICE advice and quality standards In development
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284 Technology appraisal guidance TBC Secukinumab for treating enthesitis-related arthritis or juvenile ...
National Institute for Health and Care Excellence5d
Guidance and quality standards Awaiting development
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] Technology appraisal guidance Tucatinib ...
National Institute for Health and Care Excellence5d
Guidance and quality standards Awaiting development
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...
National Institute for Health and Care Excellence10d
Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [ID6455]
For further information on how we select topics for development, please see our page about topic selection ...
National Institute for Health and Care Excellence12d
Guidance, NICE advice and quality standards In development
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] Technology appraisal guidance TBC Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small ...
National Institute for Health and Care Excellence8d
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
22 November 2022 Scope consultation end date extended by one week from 24/11/2022 until 01/12/2022. For further information on the guideline development process, please see how we develop NICE ...
National Institute for Health and Care Excellence11d
Surgical care
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
National Institute for Health and Care Excellence12d
Guidance, NICE advice and quality standards In development
Tenecteplase for treating acute ischaemic stroke [ID6306] Technology appraisal guidance 24 July 2024 Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of ...